Search the Newsreel

Nanjing Leads Biolabs Completes Phase II Enrollment for Opamtistomig in Biliary Tract Cancer

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences, Inc. (GILD) has seen its stock outperform the broader market, driven by FDA approval for its breast cancer drug Trodelvy®. Analysts maintain a "Strong Buy" consensus rating for GILD, with an average price target indicating a significant upside. Despite an expected EPS …

Canadian Large Cap Leaders Split Corp. Class A Revenue Breakdown – TSX:NPS

Gilead Sciences Inc. stock outperforms competitors despite losses on the day

Gilead Sciences Inc. (GILD) saw its stock shed 1.09% to $131.28 on Thursday, marking its second consecutive day of losses. This occurred despite a generally favorable trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both experiencing …

Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

The upcoming report from Gilead Sciences (GILD) is expected to reveal quarterly loss of -$7.07 per share, indicating a decline of 451.7% compared to the year-ago period. Analysts forecast revenues of $7.37 billion, representing an increase of 4% year over year. The consensus EPS …

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this HIV and hepatitis C drugmaker have …

Gilead Stock: Buy The Distortion Before Q2 Clears It Up (NASDAQ:GILD)

Gilead Sciences (GILD) is presented as a strong buy, despite a temporary $11.5 billion impairment, research, and development (IPR&D) charge that may negatively impact short-term optics but not the company's long-term fundamentals. The article highlights GILD's growing HIV franchise, its emerging oncology pipeline driven …

Gilead (GILD) Stock Stays Cheap On Its 130% Five Year Run

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences stock has delivered a strong 130.1% return over the past 5 years, which raises a clear question for investors about how much …

Gilead Sciences (GILD) Following Trodelvy Progress And A Fair Value Debate

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Gilead Sciences (GILD) is back in focus after regulators in Europe issued a positive opinion on expanding Trodelvy's use alongside Keytruda for certain …

How Investors May Respond To Gilead Sciences (GILD) EMA Backing Trodelvy Plus Keytruda In First-Line TNBC

The European Medicines Agency's committee has adopted a positive opinion backing Gilead Sciences' Trodelvy in combination with Merck's Keytruda as a first-line treatment for certain adults with advanced triple-negative breast cancer. This recommendation, based on strong Phase 3 data, strengthens Gilead's oncology narrative, with …

Gilead to Report Q2 Earnings: How Should You Play the Stock Now?

Gilead Sciences is set to report its second-quarter earnings on August 4th, with analysts forecasting $7.37 billion in sales and a $7.07 loss per share. While the company's HIV franchise, led by Biktarvy and Yeztugo, continues to drive strong growth and is poised for …

BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.

Off-the-shelf CAR-T therapies are emerging as a potential alternative to autologous treatments, with companies like Caribou Biosciences positioning their drugs to fill market gaps rather than directly compete with established treatments from Gilead and Bristol Myers Squibb. Caribou's vispa-cel, for instance, showed promising progression-free …

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Atea Pharmaceuticals Inc. announced on Tuesday positive topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis …

WAM Leaders declares fully franked interim dividend

Gilead Sciences, Inc. Revenue Breakdown – BIVA:GILD

This article provides a revenue breakdown for Gilead Sciences, Inc. (BIVA:GILD), highlighting its top-performing segment and key regional contributions. Last year, the company generated 530.79 billion MXN, with the Human Immunodeficiency Virus segment accounting for 374.11 billion MXN and the United States being the …

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Gilead Sciences (GILD) recently outperformed the stock market, closing up 2.91% while the S&P 500 gained only 0.21%. Over the past month, the stock has climbed 3.32%, surpassing the Medical sector's loss. The company is set to report earnings on August 4, 2026, with …

Is Gilead Sciences (GILD) Overvalued Following Its Trodelvy Europe Expansion Win?

Gilead Sciences (GILD) is under scrutiny after the European Medicines Agency's committee backed the use of its drug Trodelvy for certain breast cancer patients. Despite strong share price performance over the past year, the company's valuation is debated, with one narrative suggesting it's 1.7% …

Gilead Sciences stock may move 4.3% on August earnings report By Investing.com

Gilead Sciences Inc. (NYSE:GILD) stock is projected to move 4.3% following its upcoming August 4 earnings report, according to options data compiled by Bloomberg. Historical data indicates that the stock's actual movement has sometimes exceeded options traders' anticipation, with past earnings reports showing both …

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Wall Street expects a year-over-year decline in earnings on higher revenues when Gilead Sciences (GILD) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term …

Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating

Barclays has adjusted its price target for Gilead Sciences (GILD) to $145, down from the previous $155, while reiterating an "Equalweight" rating on the stock. This update reflects a revised valuation perspective from the firm. The article also provides a brief company profile, detailing …

Is Canadian Large Cap Leaders Split Corp. Class A's 13.9% Dividend Yield Sustainable for Long-Term Investors?

Gilead Sciences Inc (GILD) Financial Health: Profitability & Balance Sheet Analysis

Gilead Sciences Inc (GILD) has a strong financial health score of 8.91, ranking 29th out of 155 in the Pharmaceuticals industry, indicating stable financial status and high operating efficiency. The company reported a quarterly revenue of $6.96 billion, marking a 4.39% year-over-year increase, and …

Lead Real Estate Co Ltd (LRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides an overview of Lead Real Estate Co Ltd (LRE) but states that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. It includes basic stock information like current price, market cap, …

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

AstraZeneca's push for "Chinese speed" and ambitious 2030 sales goals are intensifying scrutiny on the pharmaceutical and biotech sectors. This article highlights Krystal Biotech, TG Therapeutics, and Gilead Sciences as examples of companies whose trajectories are particularly exposed to these industry-wide shifts. It details …

Lead Real Estate Co Ltd (LRE) Income Statement

This article provides the income statement for Lead Real Estate Co Ltd (LRE), offering insights into its financial performance. It includes FAQs on how to interpret income statements, key metrics for analyzing LRE stock, and specific financial figures for fiscal year 2025, such as …

Lead Real Estate Co Ltd (LRE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Lead Real Estate Co Ltd (LRE), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, individual investors, and investment advisors, along with a historical overview of institutional shareholding and recent changes in …

Lead Real Estate Co Ltd (LRE) Cash Flow

This article provides an overview of Lead Real Estate Co Ltd's (LRE) cash flow statement, detailing its operating, investing, and financing cash flows. It highlights key financial figures such as 21.50M in operating cash flow in fiscal 2025 and 5.12M in free cash flow …

FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It

Quick Read FBT's equal-weight design beat IBB by 35 percentage points over five years, returning 47% versus IBB's 13% despite carrying a higher expense ratio. IBB puts nearly 30% into four mega-caps (Vertex, Amgen, Gilead, and Regeneron), making it behave more like a defensive …

Lead Real Estate Co Ltd (LRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lead Real Estate Co Ltd (LRE), detailing its support, resistance, indicators, and moving averages. It includes an overview of various technical indicators like MACD, RSI, and ATR, along with their current values and directions, and analyzes moving …

Lead Real Estate Co Ltd (LRE) Valuation: PE, PB & Fair Value Analysis

This article provides an overview of Lead Real Estate Co Ltd (LRE) including its stock price, market cap, and P/E TTM. It notes that relevant P/E data has not yet been disclosed by the company. The page also outlines various analytical dimensions available on …

Lead Real Estate Co Ltd (LRE) Institutional Confidence

This article provides details on the institutional confidence for Lead Real Estate Co Ltd (LRE). It lists key shareholders and their shareholdings, noting the significant share held by Nagahara (Eiji). The report also highlights recent changes in institutional holdings, with several entities like Susquehanna …

Gilead (GILD) Wins Key Europe Backing For Trodelvy In Triple Negative Breast Cancer

Gilead Sciences received a positive opinion from the European Medicines Agency’s CHMP for Trodelvy combined with Keytruda to treat PD-L1 positive metastatic triple-negative breast cancer. This recommendation is based on strong Phase 3 data showing reduced disease progression or death. The European Commission's subsequent …

LRE|Lead Real Estate Co Ltd|Price:1.315|Chg%:-0.005

This article provides a comprehensive stock analysis of Lead Real Estate Co Ltd (LRE) on TradingKey, noting the absence of a stock score due to insufficient data. It details the methodologies TradingKey uses to generate various scores, including financial health, company valuation, earnings forecast, …

Gilead Sciences (GILD) Gets a Hold from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD) with a price target of $120.00. Goldman Sachs also issued a Hold rating, while BMO Capital assigned a Buy rating. Gilead reported Q1 revenue of $6.96 billion and a net profit …

Lead Real Estate Co Ltd LRE Balance Sheet

This article provides a detailed balance sheet for Lead Real Estate Co Ltd (LRE), presenting both quarterly and annual financial data. It covers various asset and liability categories, including cash, receivables, inventory, fixed assets, short-term and long-term debts, and shareholders' equity. The data allows …

Gilead Sciences Inc. stock underperforms Friday when compared to competitors

Gilead Sciences Inc. (GILD) saw its stock slide by 1.18% on Friday, closing at $129.31 despite a generally favorable day for the stock market, where the S&P 500 Index and Dow Jones Industrial Average both rose. This performance broke a two-day winning streak for …